Barry D Hock

Summary

Affiliation: Christchurch School of Medicine and Health Sciences
Country: New Zealand

Publications

  1. ncbi request reprint Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients
    B D Hock
    Haematology Research Group, Christchurch Hospital, New Zealand
    Tissue Antigens 67:57-60. 2006
  2. ncbi request reprint Circulating levels and clinical significance of soluble CD86 in myeloma patients
    B D Hock
    Haematology Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Br J Haematol 133:165-72. 2006
  3. ncbi request reprint Exposure to the electrofusion process can increase the immunogenicity of human cells
    Barry D Hock
    Haematology Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Cancer Immunol Immunother 54:880-90. 2005
  4. ncbi request reprint Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies
    B D Hock
    Haematology Research Group, Christchurch Hospital, New Zealand
    Leuk Lymphoma 45:2111-8. 2004
  5. ncbi request reprint The soluble form of CD83 is present at elevated levels in a number of hematological malignancies
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Leuk Res 28:237-41. 2004
  6. ncbi request reprint The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 98:1681-8. 2003
  7. doi request reprint Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia
    B D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Leuk Res 33:1089-95. 2009
  8. ncbi request reprint Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 106:2148-57. 2006
  9. ncbi request reprint Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients
    B D Hock
    Haematology Research Group, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand
    Leukemia 16:865-73. 2002
  10. pmc Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Immunology 137:249-58. 2012

Detail Information

Publications16

  1. ncbi request reprint Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients
    B D Hock
    Haematology Research Group, Christchurch Hospital, New Zealand
    Tissue Antigens 67:57-60. 2006
    ..These molecules may play a role in modulating immune responses within the rheumatoid joint...
  2. ncbi request reprint Circulating levels and clinical significance of soluble CD86 in myeloma patients
    B D Hock
    Haematology Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Br J Haematol 133:165-72. 2006
    ..In conclusion, this study demonstrated that sCD86 levels are a significant independent prognostic marker in at least some myeloma treatment groups and its biological role and prognostic value should be further investigated...
  3. ncbi request reprint Exposure to the electrofusion process can increase the immunogenicity of human cells
    Barry D Hock
    Haematology Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Cancer Immunol Immunother 54:880-90. 2005
    ..These findings suggest that EF protocols should be evaluated with regard to the possibility that DC-tumour hybrids may not contribute all, or even most, of the immunostimulatory capacity present in preparations of EF treated cells...
  4. ncbi request reprint Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies
    B D Hock
    Haematology Research Group, Christchurch Hospital, New Zealand
    Leuk Lymphoma 45:2111-8. 2004
    ....
  5. ncbi request reprint The soluble form of CD83 is present at elevated levels in a number of hematological malignancies
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Leuk Res 28:237-41. 2004
    ..We conclude that malignant cells are a potential source of sCD83 and that it may have functional and/or prognostic significance in hematological malignancies, particularly CLL and MCL...
  6. ncbi request reprint The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 98:1681-8. 2003
    ..Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown...
  7. doi request reprint Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia
    B D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Leuk Res 33:1089-95. 2009
    ..003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression...
  8. ncbi request reprint Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 106:2148-57. 2006
    ..Although soluble CD40 (sCD40) is a potential modulator of both antitumor responses and CD40-based therapies, the levels and significance of sCD40 in patients with hematologic malignancies are unknown...
  9. ncbi request reprint Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients
    B D Hock
    Haematology Research Group, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand
    Leukemia 16:865-73. 2002
    ....
  10. pmc Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Immunology 137:249-58. 2012
    ..The mechanisms underlying these distinct processes and the effects of arginase inhibitors on PMN induced cytotoxicity merit further investigation...
  11. ncbi request reprint Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule
    A D McLellan
    Haematology Immunology, Research Laboratory, Christchurch Hospital, New Zealand
    Eur J Immunol 25:2064-8. 1995
    ..These results demonstrate that CD86 is both the earliest and functionally the predominant co-stimulatory CD28/CTLA-4 ligand on DC...
  12. ncbi request reprint A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera
    B D Hock
    Haematology/Immunology Research Group, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand
    Int Immunol 13:959-67. 2001
    ..6 pg/ml) of circulating sCD83. Further studies utilizing purified sCD83 and the analysis of sCD83 levels in disease may provide clues to the function and ligand(s) of CD83...
  13. doi request reprint Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Nephrol Dial Transplant 27:402-10. 2012
    ....
  14. ncbi request reprint Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation
    B D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Bone Marrow Transplant 30:733-40. 2002
    ....
  15. ncbi request reprint Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor
    Sarah C Saunderson
    Department of Microbiology and Immunology, Christchurch School of Medicine, University of Otago, Dunedin, New Zealand
    J Immunol 180:8146-52. 2008
    ..Together, these results suggest that exosome release is not constitutive activity of B cells, but may be induced following cell: cell signaling...
  16. doi request reprint Suppression of CD3/CD28 antibody stimulated responses by human granulocytic myeloid-derived suppressor cells: Fact or artefact?
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand Electronic address
    Immunol Lett 152:151-2. 2013
    ..In the absence of controls to evaluate potential antibody associated artefacts considerable caution should be applied to the use and interpretation of this assay system as a means of defining suppressive G-MDSC populations. ..